We tested the expression of UBL3 in 86 NSCLCs (Table 1) by quantitative reverse transcription polymerase chain reaction (qRT-PCR) (Figure 2M), Western blot analysis (Figure 2N and 2O), and immunohistochemistry (IHC) (Figure 2P and 2Q), and observed a decrease in UBL3 expression in tumor tissues of 59/86 (68.6%) patients, demonstrating the suppressed expression of UBL3 in NSCLCs. The gene discussed is UBL3; the disease is neoplasm.